Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | TPH1 | P17752 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | PRLHR | P49683 | 1/20 | 0.31 |
| ▸ | STK4 | Q13043 | 1/20 | 0.30 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072286 | 0.94 | PDE5A (0.32) | AKR1B1KDM4EALDH1A1HSD17B10IRAK4 | |
| SCHEMBL6072844 | 0.91 | ACLY (0.41) | ACLYGAAKDM4EALDH1A1PLK1 | |
| SCHEMBL6072191 | 0.91 | ACLY (0.38) | ACLYGAAKDM4EALDH1A1 | |
| SCHEMBL6072164 | 0.91 | ACLY (0.38) | ACLYGAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6072061 | 0.90 | KDM4E (0.40) | ACLYGAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6072284 | 0.87 | IDO1 (0.33) | RXRAACLYKDM4EALDH1A1IRAK4 | |
| SCHEMBL6072162 | 0.86 | MKNK2 (0.42) | KDM4EALDH1A1IRAK4 | |
| SCHEMBL6072661 | 0.86 | ACLY (0.40) | ACLYGAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6072762 | 0.86 | IDO1 (0.32) | ACLYKDM4EALDH1A1 | |
| SCHEMBL6071796 | 0.86 | ALDH1A1 (0.35) | ACLYGAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | RXRA 692/4885AKR1B1 193/4885ACLY 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.